Valuing a biotech, they do not use PE ratio as initially no...

  1. 506 Posts.
    lightbulb Created with Sketch. 279
    Valuing a biotech, they do not use PE ratio as initially no earnings.

    They can use various methods but the norm is stages of success at clinical Trial plus potential.


    BIT has far more Earnings potential than Viralytics just for HIV alone.

    As mentioned by the CEO, this is highly likely to be Part of the cure.


    $24 Billion per annum just for HIV drugs forecast for 2020. HIV drug sales globally are known.


    BIT has no competitors for the target. Zilch, Zero, Nada.


    With $24 Billion forecast for Global HIV drug treatments in 2020, the potential is much larger than Viralytics.


    There is alot of nervousness regarding a potential  Stock Market crash....always in October. Its historical. Fearmongering.

    IMHO ...it is baloney. Facebook, Apple, Amazon, Netflix and Google are global behemoths making money hand over fist.

    Recent pullbacks ... are just that. A correction occurred because of new international taxes.

    All the FAANG stocks are sound.


    DYOR.


    GLA








 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)
Last
0.2¢
Change
0.000(0.00%)
Mkt cap ! $2.654M
Open High Low Value Volume
0.0¢ 0.0¢ 0.0¢ $0 0

Buyers (Bids)

No. Vol. Price($)
53 33177604 0.2¢
 

Sellers (Offers)

Price($) Vol. No.
0.3¢ 16833992 23
View Market Depth
Last trade - 16.21pm 08/07/2025 (20 minute delay) ?
BIT (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.